It may also have prognostic value – many patients presenting with UM develop CM after admission despite initiation of treatment (Mousa et al., 2020; Borgstein et al., 2022), and Ang-2/1 ratio may allow the identification of such patients (Table 1). This evidence concerns the gene ANGPT2 and cutaneous mastocytosis.